Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company has a differentiated pipeline with multiple innovative product candidates, including OCS-01 for diabetic macular edema and post-cataract surgery inflammation, licaminlimab (OCS-02) for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [3] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, aiming to enhance the health and quality of life for patients globally [3] Upcoming Events - Oculis management will participate in the Stifel 2024 Healthcare Conference on November 18-19, 2024, at the Lotte New York Palace Hotel [1] - CFO Sylvia Cheung will engage in a fireside chat on November 18, 2024, at 3:35 pm ET, with a live webcast available [2] - The company will also hold one-on-one meetings during the conference for interested investors [2]

Oculis Holding AG (OCS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.77%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.56, delivering a surprise of -30.23%.Over the last four quarters, the company has surpas ...

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024Leadership team bolstered with extensive experience in key areas as the Company advances its late-stage pipeline and prepares for commercial phaseCash, cash equivalents and short-term investments of $125.0 million as of September 30, 2024, provides cash runway into 2H 2026 ZUG, Switzerlan ...

Oculis Holding AG (OCS) shares soared 7.9% in the last trading session to close at $17.05. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 28.3% gain over the past four weeks.Earlier this month, the company announced the acceleration of patient enrollment for both the phase III DIAMOND studies evaluating OCS-01, a topical eye drop candidate for treating diabetic macular edema, and the expansion of the DIAMOND program committees w ...

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DME ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today annou ...

Company Updates - Oculis Holding AG announced that updates on the DIAMOND Phase 3 program for OCS-01, a high-concentration dexamethasone eye drop, will be presented at Innovate Retina and Eyecelerator 2024 [1] - Dr David Eichenbaum will present the OCS-01 Phase 3 DIAMOND program results at Innovate Retina, while Dr Riad Sherif will present at Eyecelerator 2024, highlighting upcoming milestones including the ACUITY Phase 2 trial results for OCS-05 [1][3] - The DIAMOND Phase 3 program includes two trials, DIAMOND-1 and DIAMOND-2, aiming to enroll 350 patients each to evaluate the efficacy and safety of OCS-01 eye drops for diabetic macular edema (DME) [2][6] Product Pipeline - OCS-01 is a novel topical eye drop leveraging Oculis' OPTIREACH® technology, designed to treat DME non-invasively, contrasting with current invasive therapies like intravitreal injections [5] - OCS-05 is an investigational neuroprotective therapy targeting acute optic neuritis (AON) and other neuro-ophthalmic diseases, with Phase 2 ACUITY trial results expected by the end of 2024 [8][10] - Oculis' pipeline also includes licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease and non-infectious anterior uveitis [13] Clinical Trials - The DIAMOND Phase 3 trials are double-masked, randomized, multi-center studies evaluating OCS-01 eye drops in DME patients, with primary endpoints focusing on visual acuity and central subfield thickness at Week 52 [6] - The Phase 2 ACUITY trial for OCS-05 is a randomized, double-blind, placebo-controlled study assessing the safety and tolerability of OCS-05 in AON patients, with potential applications in neuroprotection [10] Market and Disease Context - Diabetic macular edema (DME) affects approximately 37 million people globally, with prevalence expected to rise to 53 million by 2040 due to increasing diabetes rates [7] - Acute optic neuritis (AON) is a rare disease affecting up to 5 in 100,000 people annually, often leading to permanent visual impairment and frequently associated with multiple sclerosis [11][12] Industry Events - Innovate Retina focuses on advancements in retinal care, including diabetic retinopathy, gene therapy, and ocular imaging, while Eyecelerator highlights industry trends and innovative eye care products [4][5]

Oculis Holding AG (OCS) shares ended the last trading session 8.2% higher at $14.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The company is developing OCS-01, a topical eye drop candidate for treating diabetic macular edema and inflammation and pain following cataract surgery, OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease and ...

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companies The appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of ...

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with EURETINA, today announced the winner of the Inaugural Ramin Tadayoni Award. The Ramin Tadayoni Award was established in memory of Oculis' Chief Scientific Officer and a worldrenowned retina specialist in order to pay a lasting tribute to Professor Tadayoni's legacy, who passed away unexpectedly earlie ...

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be attending and presenting at the following upcoming investor conferences: Wells Fargo Healthcare Conference 2024 Event dates: September 4-6, 2024 Location: Encore Boston Harbor, Boston, MA H.C. Wainwright 26th Annual Global Investment Conference Event dates: September 9-11, 202 ...